Background
Methods
Collection of data
Statistical analyses
Results
Characteristics | Median (IQR) | Yes/total; %yes |
---|---|---|
Age (years) | 28 (24 to 34) | – |
Age difference (years) between partners | 4 (2 to 9) | – |
HIV positive | – | 37/990 (4%) |
Consistent condom use for RAI with RSP* | – | 350/905 (39%) |
Consistent condom use for RAI with CSP* | – | 733/894 (82%) |
Consistent condom use for IAI with RSP* | – | 335/899 (37%) |
Consistent condom use for IAI with CSP* | – | 716/893 (80%) |
Reported one or more CSP for AI in last 3 months | – | 440/990 (44%) |
Number of CSP in last 3 months for those with CSP. | 3 (2 to 5) | – |
Site-specific gonorrhoea in the male partners of men with urethral gonorrhoea.
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Urethra -ve | Urethra +ve | Total | |||||
P1 | Urethra -ve | 926 | 31 | 957 | 3.2% (2.2 to 4.6) | Ref | Ref |
Urethra +ve | 31 | 2 | 33 | 6.1% (0.7 to 20.2) | 1.9 | 0.3 | |
Total | 957 | 33 | 990 | 3.3% (2.3 to 4.6) | (0.4 to 8.4) | (0.1 to 1.8) | |
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Pharynx -ve | Pharynx +ve | Total | |||||
P1 | Urethra -ve | 942 | 15 | 957 | 1.6% (0.9 to 2.6) | Ref | Ref |
Urethra +ve | 22 | 11 | 33 | 33.3% (18.0 to 51.8) | 31.4*** | 4.6* | |
Total | 964 | 26 | 990 | 2.6% (1.7 to 3.8) | (13.0 to 76.1) | (1.2 to 17.1) | |
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Rectum -ve | Rectum +ve | Total | |||||
P1 | Urethra -ve | 931 | 26 | 957 | 2.7% (1.8 to 4.0) | Ref | Ref |
Urethra +ve | 11 | 22 | 33 | 66.7% (48.2 to 82.0) | 71.6*** | 48.1*** | |
Total | 942 | 48 | 990 | 4.8% (3.6 to 6.4) | (31.5 to 162.9) | (18.3 to 126.7) |
Site-specific gonorrhoea in the male partners of men with pharyngeal gonorrhoea
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Urethra -ve | Urethra +ve | Total | |||||
P1 | Pharynx -ve | 942 | 22 | 964 | 2.3% (1.4 to 3.4) | Ref | Ref |
Pharynx +ve | 15 | 11 | 26 | 42.3% (23.4 to 63.1) | 31.4*** | 18.3*** | |
Total | 957 | 33 | 990 | 3.3% (2.3 to 4.6) | (13.0 to 76.1) | (6.9 to 48.8) | |
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Pharynx -ve | Pharynx +ve | Total | |||||
P1 | Pharynx -ve | 944 | 20 | 964 | 2.1% (1.3 to 3.2) | Ref | Ref |
Pharynx +ve | 20 | 6 | 26 | 23.1% (9.0 to 43.6) | 14.2*** | 2.5 | |
Total | 964 | 26 | 990 | 2.6% (1.7 to 3.8) | (5.1 to 39.0) | (0.7 to 8.4) | |
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Rectum -ve | Rectum +ve | Total | |||||
P1 | Pharynx -ve | 927 | 37 | 964 | 3.8% (2.7 to 5.3) | Ref | Ref |
Pharynx +ve | 15 | 11 | 26 | 42.3% (23.4 to 63.1) | 18.4*** | 8.9*** | |
Total | 942 | 48 | 990 | 4.8% (3.6 to 6.4) | (7.9 to 42.8) | (3.2 to 24.6) |
Site-specific gonorrhoea in the male partners of men with rectal gonorrhoea
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Urethra -ve | Urethra +ve | Total | |||||
P1 | Rectum -ve | 931 | 11 | 942 | 1.2% (0.6 to 2.1) | Ref | Ref |
Rectum +ve | 26 | 22 | 48 | 45.8% (31.4 to 60.8) | 71.6*** | 63.9*** | |
Total | 957 | 33 | 990 | 3.3% (2.3 to 4.6) | (31.5 to 162.9) | (24.7 to 165.6) | |
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Pharynx -ve | Pharynx +ve | Total | |||||
P1 | Rectum -ve | 927 | 15 | 942 | 1.6% (0.9 to 2.6) | Ref | Ref |
Rectum +ve | 37 | 11 | 48 | 22.9% (12.0 to 37.3) | 18.4*** | 3.4 | |
Total | 964 | 26 | 990 | 2.6% (1.7 to 3.8) | (7.9 to 42.8) | (1.0 to 12.2) | |
P2 | % + ve (95% CI) | Crude OR (95% CI) | Adjusted ORa (95% CI) | ||||
Rectum -ve | Rectum +ve | Total | |||||
P1 | Rectum -ve | 910 | 32 | 942 | 3.4% (2.3 to 4.8) | Ref | Ref |
Rectum +ve | 32 | 16 | 48 | 33.3% (20.4 to 48.4) | 14.2*** | 6.9*** | |
Total | 942 | 48 | 990 | 4.8% (3.6 to 6.4) | (7.1 to 28.5) | (2.4 to 20.3) |